Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Metabolic Fingerprinting of Serum and Seminal Plasma of Testicular Cancer Patients Using Raman Spectroscopy: A Pilot Study

Authors
1 Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran; Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
2 Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3 Department of Medical Physics, Tarbiat Modares University, Tehran, Iran
4 Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Medical Bioscience, University of the Western Cape, Bellville, South Africa; LogixX Pharma, Theale, Berkshire, UK
5 Avicenna Fertility Center, Avicenna Research Institute, ACECR, Tehran, Iran, Tehran, Iran
6 Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
7 Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
Abstract
Background: Testicular cancer (TC) is a relatively rare type of cancer in men. Early diagnosis of TC remains challenging. Metabolomics holds promise in offering valuable insights in this regard. In this study, a metabolic fingerprinting approach was employed to identify potential biomarkers in both serum and seminal plasma of TC patients. Methods: A total of 9 patients with testicular cancer and 10 controls were included in the study. The metabolic fingerprinting approach was utilized as a rapid diagnostic tool to analyze the metabolome in serum and seminal plasma of TC patients in comparison to fertile men. Raman spectroscopy was applied for the analysis of metabolites in these biological samples. Results: Principal component analysis (PCA) and functional group analysis showed that the differentiation between serum samples from healthy men and TC patients was not possible. However, when analyzing seminal plasma, a significant difference was found between the two groups (p<0.05). Functional group analysis of serum only showed an increase in tryptophan concentration ratio in TC patients as compared to healthy men (p=0.03). In contrast, in seminal plasma of TC patients, this increase was observed in all analyzed compounds, including phenylalanine, tyrosine, lipids, proteins, phenols (p<0.001). Conclusion: Our study highlights the potential of metabolic fingerprinting as a fast diagnostic tool for screening TC patients, with seminal plasma serving as a valuable biological sample. Furthermore, several potential biomarkers, particularly phenylalanine, were identified in seminal plasma. This research contributes to our understanding of TC pathogenesis and has the potential to pave the way for early detection and personalized treatment approaches.
Keywords

  1. Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, et al. Testicular cancer. Nat Rev Dis Primers. 2018;4(1):29.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
  4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide. IARC. Cancer Base. 2013. 11.
  5. Milardi D, Grande G, Vincenzoni F, Pierconti F, Pontecorvi A. Proteomics for the identification of biomarkers in testicular cancer-review. Front Endocrinol (Lausanne). 2019;10:462.
  6. Leman ES, Gonzalgo ML. Prognostic features and markers for testicular cancer management. Indian J Urol. 2010;26(1):76-81.
  7. McGlynn KA, Cook MB. Etiologic factors in testicular germ-cell tumors. Future Oncol. 2009;5(9):1389-402.
  8. Adra N, Einhorn LH. Testicular cancer update. Clin Adv Hematol Oncol. 2017;15(5):386-96.
  9. Koši Kunac A, Gnjidić M, Antunac Golubić Z, Gamulin M. Treatment of germ cell testicular cancer. Acta Clin Croat. 2020;59(3):496-504.
  10. Daugaard G, Gundgaard MG, Mortensen MS, Agerbæk M, Holm NV, Rørth M, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014;32(34):3817-23.
  11. Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66(6):1172-8.
  12. Kier MG, Lauritsen J, Mortensen MS, Bandak M, Andersen KK, Hansen MK, et al. Prognostic factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study. Eur Urol. 2017;71(2):290-8.
  13. Nicholson BD, Jones NR, Protheroe A, Joseph J, Roberts NW, Van den Bruel A, et al. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: a diagnostic test accuracy systematic review. Cancer Epidemiol. 2019;59:15-21.
  14. Lakpour N, Saliminejad K, Ghods R, Reza Sadeghi M, Pilatz A, Khosravi F, et al. Potential biomarkers for testicular germ cell tumour: risk assessment, diagnostic, prognostic and monitoring of recurrence. Andrologia. 2021;53(4):e13998.
  15. Lakpour N, Ghods R, Sadeghi MR, Ranjbar MM, Abolhasani M, Kiani J, et al. Production and characterization of a new specific monoclonal antibody against A‐isoform of SALL4: a novel emerging testicular cancer marker. Andrologia. 2022;54(1):e14608.
  16. Fiehn O. Metabolomics--the link between genotypes and phenotypes. Plant Mol Biol. 2002;48(1-2):155-71.
  17. Weckwerth W. Metabolomics in systems biology. Ann Rev Plant Biol. 2003;54:669-89.
  18. Goodacre R. Metabolomics of a superorganism. J Nutr. 2007;137(1 Suppl):259S-66S.
  19. Shulaev V. Metabolomics technology and bioinformatics. Brief Bioinform. 2006;7(2):128-39.
  20. Liu X, Locasale JW. Metabolomics: a primer. Trends Biochem Sci. 2017;42(4):274-84.
  21. Kumamoto Y, Harada Y, Takamatsu T, Tanaka H. Label-free molecularimaging and analysis by raman spectroscopy. Acta Histochem Cytochem. 2018;51(3):101-10.
  22. Zhang S, Qi Y, Tan SP, Bi R, Olivo M. Molecular fingerprint detection using raman and infrared spectroscopy technologies for cancer detection: a progress review. Biosensors (Basel). 2023;13(5):557.
  23. Kong K, Kendall C, Stone N, Notingher I. Raman spectroscopy for medical diagnostics--from in-vitro biofluid assays to in-vivo cancer detection. Adv Drug Deliv Rev. 2015;89:121-34.
  24. Jones RR, Hooper DC, Zhang L, Wolverson D, Valev VK. Raman techniques: fundamentals and frontiers. Nanoscale Res Lett. 2019;14(1):231.
  25. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021.
  26. Gilany K, Mani‐Varnosfaderani A, Minai‐Tehrani A, Mirzajani F, Ghassempour A, Sadeghi MR, et al. Untargeted metabolomic profiling of seminal plasma in nonobstructive azoospermia men: A noninvasive detection of spermatogenesis. Biomed Chromatogr. 2017;31(8).
  27. Gilany K, Moazeni‐Pourasil RS, Jafarzadeh N, Savadi‐Shiraz E. Metabolomics fingerprinting of the human seminal plasma of asthenozoospermic patients. Mol Reprod Dev. 2014;81(1):84-6.
  28. Yu B, Ge M, Li P, Xie Q, Yang L. Development of surface-enhanced Raman spectroscopy application for determination of illicit drugs: towards a practical sensor. Talanta. 2019;191:1-10.
  29. Ugboma HA, Aburoma HL. Public awareness of testicular cancer and testicular self-examination in academic environments: a lost opportunity. Clinics (Sao Paulo). 2011;66(7):1125-8.
  30. Garolla A, De Giorgi U, Milardi D. Editorial: testicular cancer: new insights on the origin, genetics, treatment, fertility, general health, quality of life and sexual function. Front Endocrinol (Lausanne). 2020;11:41.
  31. Cao D, Li J, Guo CC, Allan RW, Humphrey PA. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol. 2009;33(7):1065-77.
  32. Lakpour N, Ghods R, Sadeghi MR, Ranjbar MM, Abolhasani M, Kiani J, et al. Production and characterization of a new specific monoclonal antibody against A-isoform of SALL4: a novel emerging testicular cancer marker. Andrologia. 2022;54(11):e14608.
  33. Jiang S, Liu Y, Xu Y, Sang X, Lu X. Research on liquid biopsy for cancer: a bibliometric analysis. Heliyon. 2023;9(3):e14145.
  34. Fernández-Lázaro D, García Hernández JL, García AC, Córdova Martínez A, Mielgo-Ayuso J, Cruz-Hernández JJ. Liquid biopsy as novel tool in precision medicine: origins, properties, identification and clinical perspective of cancer's biomarkers. Diagnostics (Basel). 2020;10(4):215.
  35. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-48.
  36. Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, et al. Metabolomics enables precision medicine: "a white paper, community perspective". Metabolomics. 2016;12(10):149.
  37. Worley B, Powers R. Multivariate analysis in metabolomics. Curr Metabolomics. 2013;1(1):92-107.
  38. Vasseur S, Guillaumond F. Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance. Oncogenesis. 2022;11(1):46.
  39. Platten M, Nollen EA, Röhrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379-401.
  40. Drabovich AP, Saraon P, Jarvi K, Diamandis EP. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol. 2014;11(5):278-88.
  41. Agarwal A, Saleh RA, Bedaiwy MA. Bedaiwy, Role of reactive oxygen species in the pathophysiology of human reproduction. Fertil Steril. 2003;79(4):829-43.
  42. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J. 2009;418(1):29-37.
  43. Gupta-Elera G, Garrett AR, Robison RA, O’Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev. 2012;21(2):155-62.
  44. Trachootham D, Lu W, Ogasawara MA, Valle NR, Huang P. Redox regulation of cell survival. Antioxid Redox Signal. 2008;10(8):1343-74.
  45. Akbari Z, Dijojin RT, Zamani Z, Hosseini RH, Arjmand M. Aromatic amino acids play a harmonizing role in prostate cancer: a metabolomics-based cross-sectional study. Int J Reprod Biomed. 2021;19(8):741-50.
  46. Pietkiewicz D, Klupczynska-Gabryszak A, Plewa S, Misiura M, Horala A, Miltyk W, et al. Free amino acid alterations in patients with gynecological and breast cancer: a review. Pharmaceuticals (Basel). 2021;14(8):731.
  47. Neurauter G, Grahmann AV, Klieber M, Zeimet A, Ledochowski M, Sperner-Unterweger B, et al. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett. 2008;272(1):141-7.
  48. Sharifi-Rad J, Seidel V, Izabela M, Monserrat-Mequida M, Sureda A, Ormazabal V, et al. Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy. Cell Commun Signal. 2023;21(1):89.